Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Impaired Hepatic Function Clear all
Recruiting Phase 1 Interventional

Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT07342868
View directory record Official record
Conditions
Chronic Hepaititis B Infections
Interventions
Pevifoscorvir Sodium (ALG-000184)
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)

NCT06575959
View directory record Official record
Conditions
Hepatic Insufficiency, Hepatic Impairment
Interventions
Enlicitide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

NCT00139620
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Tarceva, erlotinib, OSI-774
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Santa Monica, California • Aurora, Colorado • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

NCT05224609
View directory record Official record
Conditions
Moderate Hepatic Impairment, Severe Hepatic Impairment, Healthy Volunteers
Interventions
Lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Tustin, California • Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

NCT02474537
View directory record Official record
Conditions
Hepatic Impairment
Interventions
INC280
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

NCT01443481
View directory record Official record
Conditions
Solid Tumors, Hepatic Impairment
Interventions
Dovitinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jul 22, 2026, 8:28 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function

NCT07269301
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 74 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Lake Forest, California • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

NCT05481411
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Rialto, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Not applicable Interventional Results available

Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

NCT01439854
View directory record Official record
Conditions
Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

NCT06048302
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Saint Paul, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

NCT03562117
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

NCT00416702
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
QAB149
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2008 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

NCT06908954
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Palovarotene
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 22, 2026, 8:28 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

NCT04136444
View directory record Official record
Conditions
Healthy Study Participants, Impaired Hepatic Function
Interventions
Padsevonil
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Jul 22, 2026, 8:28 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants

NCT07250633
View directory record Official record
Conditions
Severe Hepatic Impairment, Normal Hepatic Function
Interventions
Vorasidenib 20mg
Drug
Lead sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 8:28 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

NCT05209295
View directory record Official record
Conditions
Hepatic Insufficiency, Neoplasms
Interventions
Onureg
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Iowa City, Iowa • Detroit, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

NCT02170220
View directory record Official record
Conditions
Severe Hepatic Impairment
Interventions
Vortioxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

NCT02388620
View directory record Official record
Conditions
Normal Hepatic Function, Impaired Hepatic Function
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Anaheim, California • Coral Gables, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

NCT02296905
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function

NCT07428525
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AMG 133
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

NCT02161770
View directory record Official record
Conditions
Solid Tumours
Interventions
AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
San Diego, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

NCT05857644
View directory record Official record
Conditions
Liver Diseases, Hepatic Impairment
Interventions
PF-07923568
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

NCT02397707
View directory record Official record
Conditions
HCV Infection
Interventions
Voxilaprevir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jul 22, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide in Participants With Impaired Liver Function

NCT03940742
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 22, 2026, 8:28 AM EDT